Ideaya Biosciences Inc
$ 33.91
4.31%
17 Apr - close price
- Market Cap 2,977,774,000 USD
- Current Price $ 33.91
- High / Low $ 34.66 / 32.63
- Stock P/E N/A
- Book Value 11.65
- EPS -1.28
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.09 %
- ROE -0.11 %
- 52 Week High 39.28
- 52 Week Low 16.81
About
IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected patient populations using molecular diagnostics. The company is headquartered in South San Francisco, California.
Analyst Target Price
$52.81
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-31 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-18 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-07 | 2023-08-10 | 2023-05-09 |
| Reported EPS | -0.94 | 1.33 | -0.88 | -0.82 | -1.49 | -0.6 | -0.68 | -0.53 | -0.52 | -0.46 | -0.5 | -0.49 |
| Estimated EPS | -0.937 | -0.55 | -0.79 | -0.69 | -0.6225 | -0.63 | -0.54 | -0.51 | -0.47 | -0.49 | -0.56 | -0.55 |
| Surprise | -0.003 | 1.88 | -0.09 | -0.13 | -0.8675 | 0.03 | -0.14 | -0.02 | -0.05 | 0.03 | 0.06 | 0.06 |
| Surprise Percentage | -0.3202% | 341.8182% | -11.3924% | -18.8406% | -139.3574% | 4.7619% | -25.9259% | -3.9216% | -10.6383% | 6.1224% | 10.7143% | 10.9091% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.07 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IDYA
2026-04-18 05:40:58
IDEAYA Biosciences (NASDAQ:IDYA) had its stock rating upgraded by Wall Street Zen from "sell" to "hold". This comes as the company beat its latest quarterly estimates for both EPS and revenue, with the stock trading near $33.91 and a market cap of $2.98 billion. Additionally, a director recently purchased a significant amount of shares, increasing his stake in the company.
2026-04-15 00:40:14
IDEAYA Biosciences (IDYA) shows mixed recent stock performance, contrasting with significant long-term returns. While its Price-to-Sales ratio of 13x appears overvalued compared to industry peers and its estimated fair level, a Discounted Cash Flow model suggests the stock is trading at a substantial discount. This discrepancy highlights the complexity in assessing its current valuation, urging investors to consider both the high P/S multiple against its unprofitability and the potential upside indicated by the DCF model.
2026-04-14 13:39:19
Three Bay Area cancer-fighting companies—Revolution Medicines, Allogene, and Ideaya—are reportedly looking to raise a combined $1 billion following solid clinical trial outcomes. These companies plan to seek FDA approval for their respective drugs, signaling significant advancements in their pipelines. The San Francisco Business Times highlights this development, indicating a potential surge in their market value.
2026-04-14 12:40:14
IDEAYA Biosciences announced positive topline results from its Phase 2/3 trial for darovasertib in combination with crizotinib for metastatic uveal melanoma, leading to a significant premarket stock surge. The trial met its primary endpoint with improved progression-free survival and showed higher response rates in secondary endpoints. The company plans to submit a New Drug Application to the FDA in late 2026 based on these promising results.
2026-04-14 06:08:58
IDEAYA Biosciences and French pharma company Servier announced that their combination drug for a type of eye cancer met its main goal in a mid-to-late-stage trial. This positive result led to a 21% increase in the U.S. biotech's shares and paves the way for a potential FDA application.
2026-04-14 04:39:19
IDEAYA Biosciences announced positive top-line results from its OptimUM-02 study, showing that the combination of darovasertib and crizotinib significantly improved progression-free survival (PFS) and overall response rate (ORR) in HLA-A2 negative metastatic uveal melanoma patients. The treatment arm achieved a median PFS of 6.9 months compared to 3.1 months in the control arm, alongside a higher ORR and five complete remissions. The company plans to pursue expedited regulatory pathways and explore broader development into neoadjuvant, adjuvant, and HLA-A2 positive programs.
